---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-25-000068"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2025-11-04T23:59:59+00:00"
generated_at: "2026-05-17T00:34:45.997934+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Supernus Q3 rev $192M, up 9%; growth products up 52%; ONAPGO supply constraint

## Summary
- Total revenues $192.1M (+9% YoY); combined growth product sales $149.2M (+52%).
- Qelbree net sales $81.4M (+31% YoY); GOCOVRI $40.8M (+15% YoY).
- ONAPGO net sales $6.8M in first full quarter; supply constraint pauses new patient starts.
- ZURZUVAE collab revenue $20.2M (post Sage acquisition); Q3 U.S. sales up ~150% YoY.
- Full-year 2025 revenue guidance raised; cash $281.2M at Sep 30, 2025.

## SEC filing metadata
- accession: 0001356576-25-000068
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2025-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000068/0001356576-25-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657625000068/supn-20251104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-25-000068
- JSON: https://secwatch.observer/filing/0001356576-25-000068.json
- Plain text: https://secwatch.observer/filing/0001356576-25-000068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.